Tempus AI (TEM) Stock Price, News & Analysis

Company Overview

Tempus AI, Inc. is a healthcare technology company focused on applying artificial intelligence and data analytics to precision medicine. The company combines molecular testing, clinical data and machine learning to help physicians make more informed treatment decisions and support the development of new therapies.

Tempus provides genomic and diagnostic testing services, including testing intended to identify clinically relevant mutations and other biomarkers. Its technology platform also organizes and analyzes clinical and molecular data, while its AI-enabled tools are designed to assist healthcare professionals with patient care, research and workflow management.

The company serves healthcare providers, patients, pharmaceutical companies and biotechnology researchers, primarily in the United States. Tempus was founded in 2015 by Eric Lefkofsky, who serves as its chief executive officer. The company became publicly traded on the Nasdaq under the symbol TEM in 2024.

Key Stats

• Today's Range: $61.88 to $68.94
• 50-Day Range: $41.55 to $72.69
• 52-Week Range: $40.77 to $104.32
• Volume: 8.22 million shs
• Average Volume: 6.05 million shs
• Market Capitalization: $12.42 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $69.33
• Consensus Rating: Hold

Tempus AI Stock Analysis - MarketRank™

Tempus AI scored higher than 41% of companies evaluated by MarketBeat, and ranked 457th out of 903 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.3 / 5
• Analyst Rating: Hold

Consensus Rating

Tempus AI has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 11 buy ratings, 8 hold ratings, and 2 sell ratings.

Upside/Downside

The consensus price target for Tempus AI is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Tempus AI has been the subject of 14 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Tempus AI are expected to grow in the coming year, from ($1.38) to ($1.00) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Tempus AI is -47.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Tempus AI is -47.77, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Tempus AI has a P/B Ratio of 24.92. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

21.56% of the float of Tempus AI has been sold short.

Short Interest Ratio / Days to Cover

Tempus AI has a short interest ratio ("days to cover") of 2.92, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Tempus AI has recently decreased by 1.36%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Tempus AI does not currently pay a dividend.

Dividend Growth

Tempus AI does not have a long track record of dividend growth.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 0.57

News Sentiment

Tempus AI has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.85 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 29 news articles for Tempus AI this week, compared to 10 articles on an average week.

Search Interest

56 people have searched for TEM on MarketBeat in the last 30 days. This is an increase of 10% compared to the previous 30 days.

MarketBeat Follows

17 people have added Tempus AI to their MarketBeat watchlist in the last 30 days. This is an increase of 6% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Tempus AI insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $56,963,417.00 in company stock.

Percentage Held by Insiders

24.26% of the stock of Tempus AI is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

24.22% of the stock of Tempus AI is held by institutions.

Company Calendar

• Last Earnings: 7/30/2026
• Today: 9/15/2026
• Morgan Stanley 24th Annual Global Healthcare Conference: 9/15/2026
• Next Earnings (Estimated): 11/03/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Providers & Services
• Sub-Industry: Healthcare Services
• Current Symbol: NASDAQ:TEM
• Previous Symbol: NASDAQ:TEM
• CIK: 1717115
• Web: www.tempus.com
• Phone: 800-976-5448
• Fax: N/A
• Employees: 3,800
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Tempus AI: $69.33
• High Price Target: $100.00
• Low Price Target: $35.00
• Potential Upside/Downside: +0.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.43
• Research Coverage: 21 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.44)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$245.03 million
• Net Margins: -17.77%
• Pretax Margin: -17.62%
• Return on Equity: -50.28%
• Return on Assets: -10.33%

Debt

• Debt-to-Equity Ratio: 3.06
• Current Ratio: 3.30
• Quick Ratio: 3.16

Sales & Book Value

• Annual Sales: $1.43 billion
• Price / Sales: 8.68
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.76 per share
• Price / Book: 24.95

Miscellaneous

• Outstanding Shares: 180,435,000
• Free Float: 136,661,000
• Market Cap: $12.42 billion
• Optionable: N/A
• Beta: 3.72